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Dr. Heiko Backes has written a letter to the editor in response to our recent article "Validity and reliability of extrastriatal [ 11 C]raclopride binding quantification in the living human brain" (Svensson et al., 2019a) . In short, Dr. Backes proposes that our findings of low or non-existing dopamine D2/3receptor (D 2/3 R) occupancy of quetiapine in extrastriatal regions could be explained by a putative presence of specific [ 11 C]raclopride binding in cerebellar grey matter, i.e. the reference region in our analysis. We are thankful for the valuable input by Dr. Backes and for the opportunity to clarify our reasoning.
We do not dispute that [ 11 C]raclopride binding is detectable in extrastriatal regions. On the contrary we specifically show several brain regions outside of striatum where the non-displaceable binding potential (BP ND ) decreases after pretreatment with quetiapine. However, the low level of detection in extrastriatal regions is below the level of meaningful quantification. The presence of some degree of extrastriatal specific binding is supported by the regional correlations between [ 11 C]raclopride and [ 18 F]fallypride binding referred to by Dr. Backes. Yet, it must be noted that these correlations were calculated using regional binding averages obtained for separate cohorts and in large influenced by the presence of high binding regions. A more suitable cross-validation would be in the setting of a within subject design. Moreover, as we show in our article, even for a region with "medium binding" such as thalamus, a large sample size (N=350) would be needed for an appropriately powered examination of a 10% between-group difference in [ 11 C]raclopride BP ND . This sample size has, to our knowledge, not been reached in any hitherto published study.
Is [ 11 C]raclopride binding quantification confounded by specific binding in cerebellum? Given the widespread use of cerebellum as reference region in D 2/3 R PET studies, much effort has been invested in identifying specific binding in this region. Detailed autoradiography using the high affinity radioligand [ 125 I]epidepride on large scale cryosections of the human brain has demonstrated that the level of specific D 2/3 R binding in cerebellar grey matter in man is approximately 1/1000 of that in putamen (Hall et al., 1996) . This may suffice for a small degree of specific binding using high-affinity radioligands such as [ 11 C]FLB457 (Narendran et al., 2011; Olsson et al., 2004) . Importantly, such minute level of D 2/3 R in the cerebellum is not likely to be a confounder in [ 11 C]raclopride studies. For instance, in a large saturation analysis based on 5 PET-measurements in each of 20 control subjects there was no support for specific binding in the cerebellum (Farde et al., 1995) . Dr. Backes is correct in that we observe a decrease in standardized uptake value (SUV) in cerebellum after pretreatment with the D 2/3 R antagonist quetiapine. Still, although a contribution of specific binding cannot be fully excluded, we find it unlikely. Mainly since a reduction in SUV after quetiapine pretreatment also is observed in centrum semiovale, a region containing only white matter and no D 2/3 R (Narendran et al., 2011) . Importantly, the view that specific binding in the cerebellum can explain our findings of lower occupancy in regions with low baseline BP ND is not in line with theory. In the setting of an occupancy study, specific binding in the reference tissue will lead to the same underestimation of occupancy in the target regions irrespective of the magnitude of baseline BP ND . Given true equilibrium conditions, the apparent occupancy can be calculated using the true fractional occupancy induced by the drug and the binding potential of the specific binding in the reference (Kegeles et al., 2008; Olsson et al., 2004) :
As discussed in our article, the explanation we find most probable for the varying regional occupancy values is rather the lower non-displaceable uptake of [ 11 C]raclopride in cerebellum compared to the target regions, (Mawlawi et al., 2001; Svensson et al., 2019b) . If non-displaceable uptake varies between reference and target regions, the error in estimated occupancy will depend upon the degrees of specific binding in both target and reference. Interestingly, in the theoretical example displayed in Figure 1 in Dr. Backes letter the non-displaceable uptake in cerebellum is ~25% lower compared to that of the target regions. This is in fact what causes the lower occupancy value in cortex compared to putamen in his example.
In short, we stay with our overall conclusion that caution must be exercised when interpreting results from reference tissue based quantification of [ 11 C]raclopride binding outside of the striatum.
